These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20031109)

  • 21. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
    Mosolov SN; Kabanov SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
    [No Abstract]   [Full Text] [Related]  

  • 22. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use.
    de Leon J
    J Clin Psychopharmacol; 2008 Apr; 28(2):125-31. PubMed ID: 18344721
    [No Abstract]   [Full Text] [Related]  

  • 23. Clozapine and typical antipsychotics.
    Ross DE
    Am J Psychiatry; 2004 Oct; 161(10):1925-6. PubMed ID: 15465996
    [No Abstract]   [Full Text] [Related]  

  • 24. [Reaction on 'Antipsychotics and metabolic abnormalities in children and adolescents; a review of the literature and some recommendations'].
    Cohen D; de Hert M
    Tijdschr Psychiatr; 2010; 52(8):605-7; author reply 608. PubMed ID: 20698002
    [No Abstract]   [Full Text] [Related]  

  • 25. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
    Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL
    J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.
    Bou Khalil R
    Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of action of atypical antipsychotics.
    Herrling PL
    Pharmacopsychiatry; 1991 Mar; 24(2):48-9. PubMed ID: 1677203
    [No Abstract]   [Full Text] [Related]  

  • 28. A clinical paradigm of delusions of parasitosis.
    Sandoz A; LoPiccolo M; Kusnir D; Tausk FA
    J Am Acad Dermatol; 2008 Oct; 59(4):698-704. PubMed ID: 18793939
    [No Abstract]   [Full Text] [Related]  

  • 29. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy.
    de Leon J; Diaz FJ
    Schizophr Res; 2007 Nov; 96(1-3):185-97. PubMed ID: 17618085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clozapine: more side effects but still the best antipsychotic.
    Kang X; Simpson GM
    J Clin Psychiatry; 2010 Aug; 71(8):982-3. PubMed ID: 20797378
    [No Abstract]   [Full Text] [Related]  

  • 31. [Long-term antipsychotics for patients with dementia - discontinue or continue treatment?].
    Renard D; de Pélichy E; von Elm E
    Praxis (Bern 1994); 2014 Jan; 103(2):109-10. PubMed ID: 24425550
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antipsychotic prescription assessment in general practice: metabolic effects].
    Gignoux-Froment F; de Montleau F; Saravane D; Verret C
    Encephale; 2012 Dec; 38(6):453-9. PubMed ID: 23200610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clozapine-induced neuroleptic malignant syndrome: clozapine monotherapy rechallenge in a case of previous NMS.
    Illing M; Ancill R
    Can J Psychiatry; 1996 May; 41(4):258. PubMed ID: 8726793
    [No Abstract]   [Full Text] [Related]  

  • 34. LDL cholesterol estimation using the Anandaraja's and Friedewald's formulas in schizophrenic patients treated with antipsychotic drugs.
    Paz E; Hermida J; Bouzas L; Brenlla J; Tutor JC
    Clin Biochem; 2008 Aug; 41(12):1002-7. PubMed ID: 18474233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 36. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolongation of clozapine-induced leukopenia with olanzapine treatment.
    Sayin A; Cosar B
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):958-9. PubMed ID: 16631295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clozapine-induced neuroleptic malignant syndrome in an adolescent.
    Matheson KM; Gray G
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):322-4. PubMed ID: 22897669
    [No Abstract]   [Full Text] [Related]  

  • 39. [Creativity and antipsychotic drugs].
    Murry P; Torrecuadrada JL
    Encephale; 1997 Sep; 23 Spec No 4():17-9. PubMed ID: 9417399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clozapine-induced akathisia in children with schizophrenia.
    Gogtay N; Sporn A; Alfaro CL; Mulqueen A; Rapoport JL
    J Child Adolesc Psychopharmacol; 2002; 12(4):347-9. PubMed ID: 12625995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.